Vernalis Strengths 

Our greatest strength is our integrated approach. In our research we bring to bear the best of both conventional and innovative drug discovery techniques.

• We pioneer fragment and structure based methods in the context of a full drug discovery capability
  • Phase 2 for Hsp90 oncology programme
  • Six development candidates since 2004
• Our scientific team has worked together for more than a decade
  • Strong, interdisciplinary team with extensive experience of developing and applying SBDD and FBDD methods

• We pragmatically adapt and apply the most effective methods
  • Extensive use of biophysical methods to validate fragment binding
  • Developed new NMR and SPR methods for fragment evolution

• We have extensive experience in tackling challenging targets
  • Success with difficult targets e.g. protein-protein interactions
  • Rapid assessment of the potential of targets for drug discovery

Continuing research collaborations with major pharmaceutical companies endorse our strengths.  Vernalis scientists are influential world figures in fragment-based discovery, speaking regularly at major conferences and with many widely cited publications.

Latest News